Mostly natural sequencing-by-synthesis for scRNA-seq using Ultima sequencing

Sean Simmons(Broad Institute), Gila Lithwick‐Yanai, Xian Adiconis(Broad Institute), Florian C. Oberstrass, Nika Iremadze, Kathryn Geiger-Schuller(Broad Institute), Pratiksha I. Thakore(Broad Institute), Chris J. Frangieh(Broad Institute), Omer Barad, Gilad Almogy, Orit Rozenblatt–Rosen(Broad Institute), Aviv Regev(Broad Institute), Doron Lipson, Joshua Z. Levin(Broad Institute)
Nature Biotechnology
September 15, 2022
Cited by 52Open Access
Full Text

Abstract

Here we introduce a mostly natural sequencing-by-synthesis (mnSBS) method for single-cell RNA sequencing (scRNA-seq), adapted to the Ultima genomics platform, and systematically benchmark it against current scRNA-seq technology. mnSBS uses mostly natural, unmodified nucleotides and only a low fraction of fluorescently labeled nucleotides, which allows for high polymerase processivity and lower costs. We demonstrate successful application in four scRNA-seq case studies of different technical and biological types, including 5' and 3' scRNA-seq, human peripheral blood mononuclear cells from a single individual and in multiplex, as well as Perturb-Seq. Benchmarking shows that results from mnSBS-based scRNA-seq are very similar to those using Illumina sequencing, with minor differences in results related to the position of reads relative to annotated gene boundaries, owing to single-end reads of Ultima being closer to gene ends than reads from Illumina. The method is thus compatible with state-of-the-art scRNA-seq libraries independent of the sequencing technology. We expect mnSBS to be of particular utility for cost-effective large-scale scRNA-seq projects.


Related Papers

No related papers found

Powered by citation graph analysis